Anti-myeloma properties and mechanism of polymethyl methacrylate bone cement and allograft bone in vitro

被引：0

作者：

Yao, Xing-Chen ^{[1
]}

Wei, Yan-Zhe ^{[1
]}

Luo, Hui ^{[1
]}

Du, Xin-Ru ^{[1
]}

机构：

[1] Capital Med Univ, Dept Orthopaed, Beijing Chao Yang Hosp, 8 Gongren Tiyuguan Nanlu, Beijing, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2019年 / 12卷 / 01期

关键词：

Polymethyl methacrylate; allograft bone; multiple myeloma; apoptosis; MULTIPLE-MYELOMA; DOSE DEXAMETHASONE; BORTEZOMIB; THERAPY;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Objective: The goal of this study was to investigate the effects of polymethyl methacrylate (PMMA) and allograft bone on apoptosis in the multiple myeloma cell line U266 and to clarify the molecular mechanism of apoptosis. Methods: Cell counting kit-8 (CCK-8) assay, flow cytometry, and Western blot were used in this study. Result: The apoptotic rate increased in U266 cells treated with PMMA bone cement extract and showed characteristic dose-dependent effects. PMMA could induce apoptosis of U266 cells via activation of Caspase-3 and inhibition of Bcl-2 expression. Conclusion: These data support that PMMA bone cement has an anti-myeloma effect and induces apoptosis of U266 cells. Allograft bone had no significant effect on the proliferation of U266 cells. PMMA bone cement should be the first choice in surgical treatment of multiple myeloma.

引用

页码：1276 / 1281

页数：6

共 16 条

[11] Bcl-2 family proteins [J].

Reed, JC .

ONCOGENE, 1998, 17 (25) :3225-3236

[12] Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma [J].

Richardson, P. G. ;

Hofmeister, C. C. ;

Raje, N. S. ;

Siegel, D. S. ;

Lonial, S. ;

Laubach, J. ;

Efebera, Y. A. ;

Vesole, D. H. ;

Nooka, A. K. ;

Rosenblatt, J. ;

Doss, D. ;

Zaki, M. H. ;

Bensmaine, A. ;

Herring, J. ;

Li, Y. ;

Watkins, L. ;

Chen, M. S. ;

Anderson, K. C. .

LEUKEMIA, 2017, 31 (12) :2695-2701

[13] Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study [J].

Takamatsu, Yasushi ;

Sunami, Kazutaka ;

Muta, Tsuyoshi ;

Morimoto, Hiroaki ;

Miyamoto, Toshihiro ;

Higuchi, Masakazu ;

Uozumi, Kimiharu ;

Hata, Hiroyuki ;

Tamura, Kazuo .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (02) :179-185

[14] International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease [J].

Terpos, Evangelos ;

Morgan, Gareth ;

Dimopoulos, Meletios A. ;

Drake, Matthew T. ;

Lentzsch, Suzanne ;

Raje, Noopur ;

Sezer, Orhan ;

Garcia-Sanz, Ramon ;

Shimizu, Kazuyuki ;

Turesson, Ingemar ;

Reiman, Tony ;

Jurczyszyn, Artur ;

Merlini, Giampaolo ;

Spencer, Andrew ;

Leleu, Xavier ;

Cavo, Michele ;

Munshi, Nikhil ;

Rajkumar, S. Vincent ;

Durie, Brian G. M. ;

Roodman, G. David .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18) :2347-U179

[15]

Tonak M, 2014, ANTICANCER RES, V34, P6459

[16] MULTIPLE RECURRENT GENOMIC DEFECTS IN FOLLICULAR LYMPHOMA - A POSSIBLE MODEL FOR CANCER [J].

YUNIS, JJ ;

FRIZZERA, G ;

OKEN, MM ;

MCKENNA, J ;

THEOLOGIDES, A ;

ARNESEN, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (02) :79-84

← 1 2 →